SkyRX NAD+ Injections Review 2026: Clinical Promise, Market Positioning, and Evidence Gaps in IV Therapy

What SkyRX NAD+ Therapy Actually Is and Why It Matters

SkyRX delivers intravenous nicotinamide adenine dinucleotide (NAD+) infusions positioned as a cellular energy optimization treatment. The company markets these injections through partnered medical centers like Meridian Medical Centre, targeting consumers seeking performance enhancement, longevity support, and symptom relief related to fatigue, cognitive decline, and metabolic dysfunction. This segment—often called “age-tech” or “longevity medicine”—has grown substantially as direct-to-consumer wellness spending in the IV therapy space exceeded $2.5 billion globally in 2024, according to industry market analysis, though the regulatory environment remains fragmented and the clinical evidence base remains nascent for most NAD+ protocols.

The NAD+ Market Landscape and Positioning

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme naturally present in all human cells, involved in energy metabolism, DNA repair, and cellular signaling. As NAD+ levels decline with age—dropping approximately 50% between ages 20 and 50 according to peer-reviewed research—supplementation has become a focal point in longevity research. SkyRX enters a competitive landscape that includes established IV wellness providers like Thorne HealthTech, CEND (Cellular Enhancement Nutrients Division), and direct competitors offering NAD+ protocols.

The North American IV nutrient therapy market was valued at approximately $1.8 billion in 2023 and is projected to grow at 8-12% annually through 2030, though this includes broader IV hydration and micronutrient categories. NAD+ therapy specifically remains a smaller segment within this market, representing estimated 12-15% of the overall IV wellness volume, with adoption concentrated in affluent urban markets and performance-oriented populations.

Service Model and Core Features

SkyRX operates through a clinical partnership model, delivering NAD+ infusions at affiliated medical centers rather than direct-to-consumer shipment. According to available information from partner centers like Meridian Medical Centre, the service includes:

Intravenous NAD+ administration in clinic settings, with treatment duration typically ranging from 2-4 hours depending on dosage protocols
Initial consultation and health screening to determine candidacy
Multiple infusion protocols (typically 250mg to 1,000mg doses) tailored to individual patient presentations
Post-treatment monitoring and follow-up assessment
Treatment packages typically ranging from single-session options to 6-10 session protocols over 8-12 weeks

The company targets individuals experiencing fatigue, cognitive cloudiness, athletic recovery needs, and age-related metabolic concerns. Marketed benefits include enhanced mitochondrial function, improved mental clarity, increased energy availability, and cellular repair acceleration—claims that rest on emerging but not yet conclusive clinical evidence.

Competitive Positioning and Comparative Analysis

SkyRX faces competition from both established and emerging NAD+ providers. Thorne HealthTech offers NAD+ products through direct clinical partnerships and retail channels, commanding significant market share in the integrated supplement-to-IV space. CEND Therapeutics provides IV NAD+ with more extensive patient intake and personalized dosing protocols, while regional IV lounges and functional medicine clinics offer NAD+ as part of broader wellness menus.

SkyRX's primary differentiation appears to be accessibility through established medical centers and simplified entry-to-treatment pathways. However, pricing data suggests positioning in the mid-to-premium segment. Comparable single NAD+ infusions at competing wellness providers range from $400-$800, with treatment packages (6-10 sessions) typically ranging from $2,400-$6,500. SkyRX pricing aligns with this range, though exact costs vary by partner location and protocol selection.

Clinical Evidence and Regulatory Considerations

This is the critical gap for consumers and practitioners to understand. NAD+ supplementation has demonstrated biochemical plausibility in cellular and animal models, with peer-reviewed research showing NAD+ augmentation can support mitochondrial function, DNA repair (via SIRT1 activation), and metabolic health markers. However, randomized controlled trials in humans receiving IV NAD+ remain limited, and most existing studies involve small sample sizes (typically 20-50 participants) or focus on specific populations (athletes, age-related neurodegenerative disease models).

The FDA does not regulate IV nutrient therapy as a pharmaceutical intervention in most cases; these treatments operate under the “supplement” and “wellness” regulatory framework, which carries significantly lower evidence requirements than pharmaceutical approval pathways. Practitioners administering NAD+ typically require medical licensing (MDs, DOs, or nurse practitioners), but the specific protocols, dosing regimens, and patient selection criteria are not standardized across the industry.

Notably, NAD+ therapy is not a standard insurance-covered treatment, and most practitioners market it as an elective wellness service. This matters because it means patient responsibility for outcomes falls entirely on the individual, and practitioners face limited liability frameworks if adverse events occur.

Pricing Structure and Value Proposition Assessment

SkyRX treatment pricing typically breaks down as follows based on available partner center information:

Single infusion: $500-$750
Package of 6 sessions: $2,700-$3,900 (approximately $450-$650 per session with package discount)
Intensive 10-session protocol: $4,000-$5,500 (approximately $400-$550 per session)
Initial consultation and baseline assessment: $150-$300 (sometimes waived with package purchase)

The value proposition rests on anticipated benefits: improved energy, cognitive function, and cellular health. However, return-on-investment analysis is speculative. If an individual experiences genuine energy improvement, elimination of brain fog, or measurable athletic recovery gains, the cost-per-benefit might justify the expense for affluent consumers. For others, the benefit-to-cost ratio remains uncertain without individual baseline measurement (biomarkers, cognitive testing, performance metrics) and post-treatment reassessment—which most wellness providers do not systematically implement.

Who This Is and Isn't For: Risk Factors and Limitations

SkyRX NAD+ therapy is not appropriate for certain populations. Individuals with active substance use disorders (particularly stimulant or opioid dependence), severe hepatic or renal dysfunction, or unmanaged cardiac conditions should avoid NAD+ infusions pending physician guidance. Pregnant and nursing individuals should not receive IV NAD+ therapy due to lack of safety data.

More broadly, the treatment is most suited to affluent individuals in good baseline health seeking performance optimization rather than disease treatment. Individuals expecting pharmaceutical-grade evidence or insurance coverage should look elsewhere. Additionally, those unwilling to commit to 6-10 sessions may experience minimal benefit; single infusions produce limited lasting effects.

Common side effects reported by NAD+ recipients include mild flushing, nausea, headache, and arm discomfort at infusion sites. Serious adverse events are rare but possible and include venous irritation, infection risk, and hemodynamic changes. The lack of standardized adverse event reporting in this industry means comprehensive safety databases don't exist.

Assessment: Clinical Promise Outpaces Evidence

SkyRX operates at the intersection of legitimate biochemistry and speculative wellness marketing. The fundamental science supporting NAD+ as a cellular energy molecule is sound; human trials demonstrating clinically significant outcomes in general populations remain absent. The company's positioning through medical centers rather than pure telehealth or supplement retail is a credibility advantage, but it doesn't resolve the evidence gap.

For prospective patients: NAD+ therapy represents a moderate-cost, low-risk-of-serious-harm intervention with unproven efficacy in healthy adults. If you pursue this treatment, establish baseline metrics (energy logs, cognitive testing via apps like CognitiveAnthem or standard neuropsych batteries, athletic performance markers), complete at least a 6-session protocol before expecting results, and reassess systematically. If you're seeking evidence-based interventions for fatigue or cognitive decline, evidence-supported alternatives (sleep optimization, exercise, stress management, proven supplementation like D3 and B vitamins) should be primary.

For practitioners: SkyRX partnership provides clinic revenue with moderate administrative overhead, but ensure informed consent documents clearly state the evidence limitations and that this is elective wellness, not disease treatment. Monitor your patient outcomes and contribute to the evidence base if possible.

Who should consider SkyRX NAD+ therapy?

Individuals in good baseline health experiencing subjective fatigue or cognitive cloudiness who have disposable income ($3,000-$5,500 for a treatment protocol) and want to explore emerging longevity interventions. Athletes and performance-focused individuals may also find value if recovery is a limiting factor. However, those with chronic illness, limited budgets, or preference for evidence-first medicine should explore alternative approaches.

How does NAD+ therapy compare to other energy/cognitive supplements?

Oral NAD+ precursors (NMN, NR) are more affordable ($30-$80 monthly) but demonstrate much lower bioavailability; IV delivery bypasses first-pass metabolism but offers limited evidence of superior outcomes. Established alternatives like CoQ10, carnitine, or B-complex supplementation carry stronger evidence in specific populations but are far less expensive and marketed with more modest claims.

Is NAD+ therapy covered by insurance?

No. NAD+ IV therapy is universally classified as an elective wellness service, not a covered medical treatment. Patients bear 100% out-of-pocket cost. Some medical spending accounts (HSAs/FSAs) may reimburse if the treating provider claims medical necessity, but this varies by plan and is not guaranteed.

What happens after the infusion series ends?

Most patients experience a decline in benefits 4-8 weeks after their last infusion as NAD+ levels return toward baseline. Maintenance protocols (monthly or quarterly infusions) are frequently recommended by providers, which adds significant ongoing costs. Long-term necessity and efficacy of maintenance remain unestablished.

DISCLAIMER: This review is for informational purposes only and does not constitute medical advice, treatment recommendation, or endorsement. NAD+ therapy is an emerging wellness intervention; individuals should consult with qualified healthcare providers before pursuing any new treatment. The information presented reflects industry analysis and available research as of 2026 and is subject to change as new evidence emerges. SkyRX and affiliated centers operate under varying regulatory frameworks; verify licensing and qualifications of practitioners before treatment. Outcomes are individual and not guaranteed. This publication does not receive compensation from SkyRX or competing providers and maintains editorial independence.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.